1 mutation 1 medicine
European collaboration
to treat 1 patient with 1 mutation
with anti-sense oligo nucleotide therapy
1 Mutation 1 Medicine (1M1M) aims to establish a scalable European platform for development and implementation of mutation-specific antisense oligonucleotide (ASO) treatments for individuals with nano-rare neurological diseases.
Collaborations
Lijst van diensten
-
Acedemic partnersLijstitem 1
- Eberhard-Karls Universität Tübingen, Germany
- Leiden University Medical Centre, Netherlands
- University College London, UK
- Medical University Vienna, Austria
- Ludwig Maximilians University Munich, Germany
- Pediatric Hospital Bambino Gesù, Italy
- Koc University, Turkey
- Sheba Medical Center, Israel
- Vall d’Hebron Barcelona Hospital, Spain
- Heidelberg University Hospital, Germany
-
Industry partnersLijstitem 2
- BianoGMP GmbH, Germany
- NCARDIA Services BV, Netherlands
- Charles River, Canada
-
Patient advocacy partnersLijstitem 3
- European Leukodystrophies Association
- EuroAtaxia
- Valeria Association
- Mila’s Miracle Foundation
Associated partners and additional collaborations
- CONSILIUM Salmonson & Hemmings
- N=1 ASO collaborative
- European Reference Network for Rare Neurological Diseases
CONTACT INFORMATION
If you have any questions please contact us with the contact form below
